Основная статистика
| LEI | 5493009JFIGUFEVPK217 |
| CIK | 897448 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amarin Corporation plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| July 30, 2025 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY As Adopted on June 29, 2025 Retainer (USD$) Annual Board Retainer Fees: Non-Executive Chair 95,000 All Non-Employee Directors (Other Than Non-Executive Chair) 62,500 Annual Chair Retainer Fees:* Audit Committee Chair 25,000 Remuneration Committee Chair 20,000 Nominating and Corporate Governance Committee Chair 11,000 Annua |
|
| July 30, 2025 |
Exhibit 99.1 Amarin Reports Second Quarter 2025 Financial Results - European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months - - Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability i |
|
| July 30, 2025 |
Exhibit 10.3 DATED: AMARIN CORPORATION PLC and xxx DEED OF INDEMNITY THIS DEED OF INDEMNITY is made on [●] BETWEEN: (1) AMARIN CORPORATION PLC, a public limited company registered in England and Wales with company number 02353920 with its principal place of business at Spaces South Docklands, Block C, 77 Sir John Roger’s Quay Dublin 2, Ireland (the "Company"); and (2) xxx (the "Indemnified Person" |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (E |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| July 23, 2025 |
Exhibit (d) July 22, 2025 JPMorgan Chase Bank, N.A., as Depositary 383 Madison Avenue, Floor 11 New York, NY 10179 Re: Registration Statement on Form F-6 – American Depositary Shares evidenced by American Depositary Receipts for deposited ordinary shares of Amarin Corporation plc Ladies and Gentlemen: We have acted as counsel to JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), in conne |
|
| July 23, 2025 |
Exhibit (a) TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Beneficial Owner 2 (e) Commission 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder 3 (l) Removal Notice Date 3 (m) Resignation Notice Date 3 (n) |
|
| July 23, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 22, 2025 As filed with the U.S. Securities and Exchange Commission on July 22, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS AMARIN CORPORATION PLC (Exact name of issuer of deposited securities as specified in its charter) N/A |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) ( |
|
| June 24, 2025 |
Exhibit 10.1 Execution Version [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the registrant treats as private or confidential. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into this 20th day of June, 2025 (the “Effective Date”) between Amarin |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| June 24, 2025 |
Exhibit 99.1 AMARIN ANNOUNCES EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH RECORDATI TO COMMERCIALIZE VAZKEPA® (ICOSAPENT ETHYL) IN EUROPE - Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow - - Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com - |
|
| May 15, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Com |
|
| May 7, 2025 |
Exhibit 99.1 Amarin Reports First Quarter 2025 Financial Results - First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® - - Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change - - Company to Host Confe |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc ( |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Comm |
|
| April 29, 2025 |
Exhibit 99.1 Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing - - Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with t |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 29, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 9, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| April 9, 2025 |
Exhibit 99.1 Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change - Action Taken to Maintain Company’s Nasdaq Listing – DUBLIN, Ireland and BRIDGEWATER, N.J., April 9, 2025 - Amarin Corporation plc (NASDAQ: AMRN), today announced that the Company’s previously announced ratio change on its American Depositary Shares (“ADS”) from one (1) ADS representing one (1) ordinary share, to the new ra |
|
| April 7, 2025 |
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors Exhibit 99.1 Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors DUBLIN, Ireland and BRIDGEWATER, N.J., April 7, 2025 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. “On behalf of the |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 12, 2025 |
Exhibit 97.1 AMARIN CORPORATION PLC COMPENSATION RECOVERY POLICY Amarin Corporation plc, a public limited company incorporated under the laws of England and Wales (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation fro |
|
| March 12, 2025 |
Special Trading Procedures for Insiders Exhibit 19.2 AMARIN CORPORATION PLC (the “Company”) SPECIAL TRADING PROCEDURES FOR INSIDERS To comply with federal and state securities laws governing insider trading, the Company has adopted these Special Trading Procedures for Insiders (“Trading Procedures”) as an addendum to the Company’s Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Policy”). These Trading |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 Amarin Corporation plc (Exact n |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2025 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| March 12, 2025 |
Exhibit (a)(i) AMARIN CORPORATION PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE AMENDED AND RESTATED DEPOSIT AGREEMENT, DATED AS OF NOVEMBER 4, 2011 Amendment No. 1 to the Amended and Restated Deposit Agreement Dated as of [●], 2025 Table of Contents Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions. |
|
| March 12, 2025 |
Exhibit 99.1 Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action - Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million - - Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlin |
|
| March 12, 2025 |
EXHIBIT 21.1 Subsidiaries of the Registrant as of December 31, 2023 Name Jurisdiction Amarin Pharmaceuticals Ireland Limited Ireland Amarin Pharma, Inc. United States Ester Neurosciences Limited Israel Amarin Switzerland GmbH Switzerland Amarin Germany GmbH Germany Amarin France SAS France Amarin UK Limited United Kingdom Amarin Italy S.r.l Italy Amarin Switzerland GmbH Sucursal Espana Spain Amari |
|
| March 12, 2025 |
Insider Trading and Disclosure Policy Exhibit 19.1 AMARIN CORPORATION PLC STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE December 9, 2019 This memorandum sets forth the policy of Amarin Corporation plc and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Tra |
|
| March 12, 2025 |
As filed with the Securities and Exchange Commission on March 12, 2025 Registration No. |
|
| March 12, 2025 |
Exhibit 99.2 Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - 1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq Listing - DUBLIN, Ireland and BRIDGEWATER, N.J., March 12, 2025 - Amarin Corporation plc (NASDAQ: AMRN), today announced its intent to effect a ratio change on its America |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| December 18, 2024 |
Exhibit 99.1 AMARIN APPOINTS PETER FISHMAN CHIEF FINANCIAL OFFICER - Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company - DUBLIN, Ireland and BRIDGEWATER, N.J., December 13, 2024 – Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He w |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 22, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation p |
|
| October 30, 2024 |
Exhibit 99.1 Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update - Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance - - Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early Phases of European Launches - - Positive European Momentum Continues with Progress from Pri |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| October 30, 2024 |
Consulting Agreement, dated July 26, 2024, by and between Amarin Corporation plc and Patrick Holt Exhibit 10.1 July 26, 2024 Mr. Patrick J. Holt Re: Consulting Agreement Dear Pat, This letter agreement (this “Agreement”) is intended to confirm our mutual understanding with respect to your limited engagement as a consultant for Amarin Corporation plc (the “Company”). By signing below, you represent and warrant that you were under no obligation to any third-party that would have interfered with |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) ( |
|
| July 31, 2024 |
Exhibit 99.1 Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - Cash Position of $307 Million Provides Stable and Strong Capital Foundation - - Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally - - Leadership Transition Completed with Appointment of Aaron Berg as President and |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (E |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| July 29, 2024 |
CEO Employment Agreement, dated July 25, 2024, by and between Amarin Corporation plc and Aaron Berg. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of this 25 day of July, 2024 (the “Effective Date”), between Amarin Corporation plc, (the “Company”) and Aaron D. Berg (the “Executive”). Payments and benefits to the Executive under this Agreement may be satisfied by a subsidiary or affiliate of the Company. WHEREAS, the Company desires to continue to employ the |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Com |
|
| June 4, 2024 |
Exhibit 99.1 AMARIN BOARD OF DIRECTORS ANNOUNCES CEO TRANSITION - Board Appoints Aaron Berg as President & CEO - - Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities - DUBLIN, Ireland and BRIDGEWATER, N.J., June 4, 2024 – Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice Pre |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Com |
|
| May 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value 50 pence each (1) 457(c) and 457(h) 16,927,178 (2) $0. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc ( |
|
| May 1, 2024 |
As filed with the Securities and Exchange Commission on May 1, 2024 As filed with the Securities and Exchange Commission on May 1, 2024 Registration No. |
|
| May 1, 2024 |
Exhibit 99.1 Amarin Reports First Quarter 2024 Business Update and Financial Results - New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 - - In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 '24 versus Q4 '23 Driven by Spain and the UK - - Current Cash Position of $308 Million; Remains Stable Over Seven Quarters - - Shar |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Comm |
|
| April 22, 2024 |
Amendment No. 3 to the Amarin Corporation plc 2020 Stock Incentive Plan Exhibit 10.2 AMARIN CORPORATION PLC AMENDMENT NO. 3 TO 2020 STOCK INCENTIVE PLAN The Amarin Corporation plc 2020 Stock Incentive Plan (the “Plan”) is hereby amended by the Board of Directors and shareholders of Amarin Corporation plc as follows: Section 2(w) of the Plan is hereby amended to read as follows: “ISO Limit” shall mean 60,000,000 Shares, subject to adjustment as provided in the Plan and |
|
| April 22, 2024 |
Amended and Restated Articles of Association of the Company Exhibit 3.1 THE COMPANIES ACTS 1985 to 2006 PUBLIC COMPANY LIMITED BY SHARES ARTICLES OF ASSOCIATION (Adopted by Special Resolution passed on 18 April 2024) -of- AMARIN CORPORATION PLC (Incorporated 1st March 1989) THE COMPANIES ACTS 1985 to 2006 PUBLIC COMPANY LIMITED BY SHARES ARTICLES OF ASSOCIATION -of- AMARIN CORPORATION PLC (Adopted by a Special Resolution passed on 18 April 2024) PRELIMINAR |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 18, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| April 22, 2024 |
Exhibit 99.1 Amarin Announces Results of Annual General Meeting of Shareholders - Shareholders Approve Share Repurchase Program of up to $50 Million - DUBLIN, Ireland and BRIDGEWATER, N.J., April 18, 2024 - Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each |
|
| April 3, 2024 |
Exhibit 99.1 Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe - Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 - DUBLIN, Ireland and BRIDGEWATER, N.J., April 3, 2024 - Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 29, 2024 |
EXHIBIT 21.1 Subsidiaries of the Registrant as of December 31, 2023 Name Jurisdiction Amarin Pharmaceuticals Ireland Limited Ireland Amarin Pharma, Inc. United States Ester Neurosciences Limited Israel Amarin Switzerland GmbH Switzerland Amarin Germany GmbH Germany Amarin France SAS France Amarin UK Limited United Kingdom Amarin Italy S.r.l Italy Amarin Switzerland GmbH Sucursal Espana Spain Amari |
|
| February 29, 2024 |
Offer Letter with Jonathan Provoost, dated October 9, 2023* Exhibit 10.43 October 9, 2023 Jonathan Noah Provoost *** Dear Jonathan, On behalf of Amarin Corporation plc (the "Company"), I am pleased to confirm our offer to employ you as Executive Vice President, Chief Legal and Compliance Officer. The initial terms and conditions of your employment, should you accept this offer, are set forth below in this letter agreement (the "Agreement"), 1. Position: Ex |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 29, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| February 29, 2024 |
Exhibit 97.1 AMARIN CORPORATION PLC COMPENSATION RECOVERY POLICY Amarin Corporation plc, a public limited company incorporated under the laws of England and Wales (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation fro |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 Amarin Corporation plc (Exact n |
|
| February 29, 2024 |
Exhibit 99.1 Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 - - Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million - - Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Mi |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 25, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| January 10, 2024 |
JANUARY 2024 42nd Annual J.P. Morgan Healthcare Conference Patrick Holt President & CEO JANUARY 2024 42nd Annual J.P. Morgan Healthcare Conference Patrick Holt President & CEO This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and lit |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2024 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| January 10, 2024 |
AMARIN PROVIDES PRELIMINARY FOURTH QUARTER 2023 SELECTED FINANCIALS AND OUTLINES KEY PRIORITIES FOR 2024 - Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 - - Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million - - 2024 Key Priorities Include Accelerating Revenue in Key European Launch Markets, Retaining IPE Market Leadership in the US and Maximizing Patient Uptake in Rest of World (RoW) Through Partnerships - - Company Announces Plan to Initiate Share Repurchase Program of Up to $50 Million - - Amarin to Present at 42nd Annual J. |
|
| December 5, 2023 |
AMRN / Amarin Corp - ADR / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| December 5, 2023 |
EXHIBIT 16 Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership Sarissa sees turnaround in progress but it will take time Sarissa has not sold any Amarin shares Greenwich, CT, December 4, 2023 - Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa believes Amarin’s stock is significantly undervalued. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| November 1, 2023 |
Exhibit 99.1 Amarin Reports Third Quarter 2023 Financial Results - Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 - - Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position of $321 Million - - Company Continues to Deliver Significant U.S. Profit Through Extended Lifecycle |
|
| November 1, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation p |
|
| October 31, 2023 |
Exhibit 99.1 AMARIN APPOINTS JONATHAN PROVOOST EXECUTIVE VICE PRESIDENT, CHIEF LEGAL & COMPLIANCE OFFICER — Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin —| DUBLIN, Ireland and BRIDGEWATER, N.J., OCTOBER 31, 2023 – Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company’s new Executive Vice President, Chief Legal & Com |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| October 24, 2023 |
Amarin Corporation plc October 24, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 5, 2023 |
AMRN / Amarin Corp - ADR / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 068 |
|
| August 11, 2023 |
VIA EDGAR August 11, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 2, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Offering of Securities: Fees to Be Paid Equity Ordinary Shares, par value £0. |
|
| August 2, 2023 |
Form of Senior Debt Security (included in Exhibit 4.4 hereto) Exhibit 4.4 AMARIN CORPORATION PLC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| August 2, 2023 |
Exhibit 99.1 Amarin Reports Second Quarter 2023 Financial Results - Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash - - Delivered Positive Cash Flow of $9 Million in the Quarter with a Cash Position of $313 Million - - Comprehensi |
|
| August 2, 2023 |
Employement Agreement between Aaron D. Berg and Amarin Corporation, plc. dated April 13, 2023 Exhibit 10.2 April 13, 2023 Via Email Aaron Berg Dear Aaron: Amarin Corporation plc (the “Company”) is pleased to extend you an offer to serve as Interim Chief Executive Officer of the Company (“Interim CEO”), reporting to the Board of Directors of the Company (the “Board”), effective April 13, 2023 (the “Effective Date”). The terms of your employment while you are in the Interim CEO role are as f |
|
| August 2, 2023 |
As filed with the Securities and Exchange Commission on August 2, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 2, 2023 Registration No. |
|
| August 2, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective May 2023 Retainer ($) Annual Board Retainer Fee: Non-Executive Chairman 95,000 All non-employee directors 62,500 Annual Chairman Retainer Fees:* Audit Committee Chairman 25,000 Remuneration Committee Chairman 20,000 Nominating and Corporate Governance Committee Chairman 11,000 Annual Committee Member Retainer Fees:* Audit Committee 1 |
|
| August 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amarin, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value 50 pence e |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (E |
|
| August 2, 2023 |
Form of Subordinated Debt Security (included in Exhibit 4.6 hereto) Exhibit 4.6 AMARIN CORPORATION PLC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certif |
|
| August 2, 2023 |
As filed with the Securities and Exchange Commission on August 2, 2023 S-8 As filed with the Securities and Exchange Commission on August 2, 2023 Registration No. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| July 25, 2023 |
Amendment No. 2 to the Amarin Corporation plc 2020 Stock Incentive Plan EX-10.2 Exhibit 10.2 AMARIN CORPORATION PLC AMENDMENT NO. 2 TO 2020 STOCK INCENTIVE PLAN The Amarin Corporation plc 2020 Stock Incentive Plan (the “Plan”) is hereby amended by the Board of Directors and shareholders of Amarin Corporation plc as follows: Section 2(w) of the Plan is hereby amended to read as follows: “ISO Limit” shall mean 50,000,000 Shares, subject to adjustment as provided in the |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 21, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| July 20, 2023 |
CEO Employment Agreement between Patrick Holt and Amarin Corporation, plc. dated July 18, 2023 EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Amarin Corporation plc, (the “Company”) |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 18, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| July 18, 2023 |
Amarin Appoints Patrick Holt as President and Chief Executive Officer EX-99.2 Exhibit 99.2 Amarin Appoints Patrick Holt as President and Chief Executive Officer DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 – Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors has appointed Patrick Holt as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. Aaron Berg, who served as In |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 18, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| July 18, 2023 |
EX-99.1 Exhibit 99.1 Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally — Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources — — Maximizes Cash Flow Opportunity Through Streamlined Model in U.S. — — Company Expects Restructuring to Drive Annual Cost Savings |
|
| June 26, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| June 8, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Sectio n 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| May 3, 2023 |
Exhibit 99.1 Amarin Reports First Quarter 2023 Financial Results and Provides Business Update - Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives - - Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing - - International Strategy Progressing with CSL |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Comm |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc ( |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| April 17, 2023 |
Exhibit 99.1 AMARIN NAMES AARON BERG INTERIM PRESIDENT & CHIEF EXECUTIVE OFFICER AND ADDS OLIVER O’CONNOR TO COMPANY’S BOARD OF DIRECTORS DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 – Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| March 6, 2023 |
Amarin Announces Board Departures EX-99.1 Exhibit 99.1 Amarin Announces Board Departures DUBLIN, Ireland and BRIDGEWATER. N.J., March 6, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members: Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murr |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| March 1, 2023 |
Guaranty dated January 20, 2023, issued by MEH, Inc. Exhibit 10.45 GUARANTY MEH, INC., a corporation organized under the laws of the state of Nevada, having an address of 675 McDonnell Blvd., Hazelwood, MO 63042, Attn: Jeffrey Hunter (the “Guarantor”) has requested that AMARIN PHARMA, INC., a Delaware corporation, having an address at 440 Route 22, Suite 300, Bridgewater, New Jersey 08807 (“Sublessor”) to enter into a Sublease Agreement of even date |
|
| March 1, 2023 |
Exhibit 10.46 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the “Sublease”) made this 20th day of January, 2023 by and between AMARIN PHARMA, INC., a Delaware corporation, having an address at 440 Route 22, Suite 300, Bridgewater, New Jersey 08807 (the “Sublessor”), and ST SHARED SERVICES LLC, a Delaware limited liability company, having an address at 675 McDonnell Blvd. St. Louis, MO 63042 (the “Su |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 Amarin Corporation plc (Exact n |
|
| March 1, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| March 1, 2023 |
LICENCE AGREEMENT Exhibit 10.47 Licensor (‘us’, ‘we’ or ‘our’): Licensee (‘you’, or ‘your’): Weston Office Solutions Ltd Amarin Pharmaceuticals Ireland Ltd T/A Iconic Offices 77 Sir John Rogerson's Quay 81 Merrion Square South D02 NP08 Dublin 2 Ireland D02 NR12 Ireland Offices(s): Company REGISTRATION NUMBER: Greenway 211-219 CENTRE: Billing contact details: The Greenway Contact name: David Keenan |
|
| March 1, 2023 |
Transition Agreement between Jason M. Marks and Amarin Corporation plc, dated December 6, 2022* Exhibit 10.31 December 1, 2022 Jason Marks Re: Transition Agreement Dear Jason: This letter confirms that your employment with Amarin Corporation plc (together with its subsidiaries and any controlled affiliates, the "Company") will be ending. We appreciate your service and contributions and would like to make this transition as smooth as possible. This letter sets forth the terms of a Transition |
|
| March 1, 2023 |
EXHIBIT 21.1 Subsidiaries of the Registrant as of December 31, 2022 Name Jurisdiction Amarin Pharmaceuticals Ireland Limited Ireland Amarin Pharma, Inc. United States Ester Neurosciences Limited Israel Amarin Switzerland GmbH Switzerland Amarin Germany GmbH Germany Amarin France SAS France Amarin UK Limited United Kingdom Amarin Italy S.r.l Italy Amarin Switzerland GmbH Sucursal Espana Spain Amari |
|
| March 1, 2023 |
Exhibit 99.1 Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization - - Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target - -European, International Strategies Advancing At-Pace with Significant Progress Throughout 2022, and |
|
| March 1, 2023 |
Exhibit 10.44 CONSENT OF LANDLORD TO SUBLEASE THIS CONSENT OF LANDLORD TO SUBLEASE (this “Consent”) is made as of January 20, 2023, among AMARIN PHARMA, INC., a Delaware corporation (“Sublessor”), ST SHARED SERVICES LLC, a New Jersey limited liability company (“Sublessee”), and LIBERTY DENVER WOOD LLC, a New Jersey limited liability company (“Landlord”). WHEREAS, Sublessor is the tenant under the |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S |
|
| February 28, 2023 |
AMRN / Amarin Corp - ADR / Sarissa Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 brhc10049017sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Managem |
|
| February 28, 2023 |
EXHIBIT 15 SARISSA CAPITAL WINS PROXY CONTEST AGAINST AMARIN BY HUGE LANDSLIDE Sarissa honored to have received 100 million more votes than Amarin board Greenwich, CT, February 28, 2023 – Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. |
|
| February 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 27, 2023 |
EXHIBIT 14 SARISSA CAPITAL CONDEMNS AMARIN BOARD FOR FRONTRUNNING RESULTS OF PROXY CONTEST WITH EGREGIOUS EQUITY GRANTS TO EXECUTIVES Sarissa believes Amarin board acted in bad faith by making these equity grants while refusing to disclose proxy contest results and will hold each director personally accountable Sarissa urges Amarin CEO Karim Mikhail to repudiate his undeserved equity grants and re-issue them to hard working Amarin employees Greenwich, CT, February 27, 2023 – Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa is appalled at this latest act of betrayal of the shareholders by the Amarin board. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 27, 2023 |
AMRN / Amarin Corp - ADR / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 068 |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 21, 2023 |
AMRN / Amarin Corp - ADR / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 068 |
|
| February 21, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporatio |
|
| February 21, 2023 |
EX-99.1 Exhibit 99.1 February 17, 2023 Bryan J. Lowrance T +1 617 951 7189 [email protected] BY EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christina Chalk Re: Amarin Corporation plc Dear Ms. Chalk: On behalf of Amarin Corporation plc (“Amarin” or the “Company”), we are writing to highlight materially misleadin |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 21, 2023 |
EXHIBIT 13 SARISSA CAPITAL URGES AMARIN SHAREHOLDERS TO VOTE FOR CHANGE AND REMAKE AMARIN FOR SHAREHOLDERS Amarin Deludes Shareholders by Presenting an Alternative Reality Where the Truth Does Not Matter Sarissa Believes that Shareholders Have Suffered Long Enough from the Nightmare under the Current Regime and Should Vote “FOR” Change at Amarin Greenwich, CT, February 17, 2023 – Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the dire need for change at Amarin Corporation plc (NASDAQ: AMRN) accessible at the link below: Presentation: https://freeamarin. |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive P |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive P |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 15, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 15, 2023 |
DFAN14A 1 ny20006859x22dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| February 15, 2023 |
AMRN / Amarin Corporation plc (ADR) / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| February 15, 2023 |
EX-12 2 ny20006859x21ex12.htm EXHIBIT 12 EXHIBIT 12 SARISSA CAPITAL DISAPPOINTED THAT AMARIN WEBCAST CONTINUES BOARD’S DEFENSE OF POOR RESULTS AND LACK OF ACCOUNTABILITY Sarissa Believes Amarin Board Missed an Opportunity for its First True Engagement with Frustrated Shareholder Base Sarissa Points to Several Statements Made by the Amarin Board Which Demonstrate a Complete Lack of Understanding of |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Stateent Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pr |
|
| February 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 14, 2023 |
AMRN / Amarin Corporation plc (ADR) / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| February 14, 2023 |
Exhibit 11 SARISSA CAPITAL WARNS OF AMARIN’S EXPENSIVE ATTEMPTS TO SWITCH VOTES BY INUNDATING SHAREHOLDERS WITH WHITE PROXY CARDS If You Already Voted a Proxy Card “FOR” the Sarissa Nominees and “FOR” the Removal of Chairman Per Wold-Olsen, There is NOTHING Else for You to Do If You Have Any Questions or Have Not Yet Received a BLUE Proxy Card, Please Contact Sarissa’s Proxy Solicitor, D. |
|
| February 13, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive P |
|
| February 10, 2023 |
EXHIBIT 10 SARISSA CAPITAL DOES NOT BELIEVE AMARIN CARES ABOUT SHAREHOLDERS Amarin Continues to Ignore the Loud and Clear Message Sent by Shareholders at the Last Shareholder Meeting Amarin’s Misleading Words Cannot Hide Its Poor Leadership and Governance Practices That Harm and Disenfranchise Shareholders Vote the BLUE proxy card “FOR” the appointment of the Sarissa Nominees and “FOR” the Removal of Chairman Per Wold-Olsen on or before February 21, 2023 Greenwich, CT, February 9, 2023 – Sarissa Capital Management LP (“Sarissa”) today issued the following letter to other shareholders of Amarin Corporation plc (NASDAQ: AMRN): Dear Fellow Amarin Shareholders: We, the owners, face an important decision at our upcoming shareholder meeting. |
|
| February 10, 2023 |
AMRN / Amarin Corporation plc (ADR) / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| February 9, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive P |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 8, 2023 |
AMRN / Amarin Corporation plc (ADR) / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| February 8, 2023 |
EXHIBIT 9 SARISSA CAPITAL HIGHLIGHTS AMARIN’S INACCURATE AND MISLEADING STATEMENTS Sarissa urges all shareholders to vote the BLUE proxy card for needed change at Amarin on or prior to February 21, 2023 Do NOT vote Amarin’s WHITE proxy card Greenwich, CT, February 7, 2023 – Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN): Sarissa today released a presentation highlighting many of the inaccurate and misleading statements Amarin made in its attempts to thwart shareholder representation and oversight on the board. |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 6, 2023 |
DEFA14A 1 d474139ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S |
|
| February 2, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive P |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S |
|
| January 31, 2023 |
DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy St |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| January 27, 2023 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 27, 2023 |
PRER14A 1 d424531dprer14a.htm PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the C |
|
| January 27, 2023 |
CORRESP 1 filename1.htm ROPES & GRAY LLP PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MA 02199-3600 WWW.ROPESGRAY.COM January 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christina Chalk Re: AMARIN CORP PLC\UK PREC14A filed January 17, 2023 SEC File No. 0-21392 Dear Ms. Chalk: On behalf of Amarin Cor |
|
| January 26, 2023 |
United States securities and exchange commission logo January 25, 2023 Russell L. Leaf Partner Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, New York 10019 Re: AMARIN CORP PLC\UK PREC14A filed January 18, 2023 Filed by Sarissa Capital Catapult Fund LLC et al. SEC File No. 0-12392 Dear Russell L. Leaf: We have reviewed your filing and have the following comments. In some of our comments |
|
| January 25, 2023 |
United States securities and exchange commission logo January 25, 2023 Bryan J. Lowrance Partner Ropes & Gray LLP Prudential Tower 800 Boylestown Street Boston, MA 02199 Re: AMARIN CORP PLC\UK PREC14A filed January 17, 2023 SEC File No. 0-21392 Dear Bryan J. Lowrance: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with informatio |
|
| January 23, 2023 |
DEFA14A 1 d429258ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| January 19, 2023 |
EXHIBIT 8 Sarissa Capital Calls Out Amarin’s Sham Board Refreshment Sarissa puts little faith in Chairman Per Wold-Olsen’s board refreshment process that resulted in NO SHAREHOLDER REPRESENTATIVES ON THE BOARD Sarissa believes the board’s refusal to consider shareholder input on the board despite Amarin’s failures indicates the current board does not prioritize interests of shareholders Greenwich, CT, January 18, 2023 – Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN): In 2022 alone, Amarin stock lost over two-thirds of its value, and shareholders lost over $840 million in equity. |
|
| January 19, 2023 |
AMRN / Amarin Corporation plc (ADR) / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| January 17, 2023 |
PREC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| January 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 11, 2023 |
EX-99.2 3 s58919650c.htm EXHIBIT 5 - PRESS RELEASE, JANUARY 10, 2023 EXHIBIT 5 SARISSA CAPITAL SUBMITS NOTICE TO CALL A SPECIAL MEETING OF AMARIN SHAREHOLDERS TO ADD DIRECTORS AND REMOVE CHAIRMAN PER WOLD-OLSEN Sarissa believes current board lacks any remaining credibility for representing shareholders Sarissa is astonished that Amarin board refuses to add shareholder representatives Greenwich, CT |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| January 11, 2023 |
EX-99.3 4 s58919650d.htm EXHIBIT 6 - JOINT FILING AGREEMENT OF THE REPORTING PERSONS EXHIBIT 6 JOINT FILING AGREEMENT In accordance with Rule 13d−1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Ordinary Shares of Amarin Corpora |
|
| January 11, 2023 |
EX-99.4 5 s58919650e.htm EXHIBIT 7 - POWER OF ATTORNEY EXHIBIT 7 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS THAT the undersigned hereby constitutes and appoints Mark DiPaolo and Patrice Bonfiglio and each of them severally, as the true and lawful attorneys and agents of the undersigned, with power to act with or without the others and with full power of substitution and resubstitution, to ex |
|
| January 11, 2023 |
EX-99.1 2 s58919650b.htm EXHIBIT 4 - REQUISITION NOTICE, JANUARY 10, 2023 EXHIBIT 4 The Directors Amarin Corporation plc 77 Sir John Rogerson’s Quay Block C Grand Canal Docklands Dublin 2, Ireland January 10, 2023 Dear Sirs Request to convene a general meeting of Amarin Corporation plc (“Company”) and special notice of a resolution to remove a director of the Company, if applicable Pursuant to sec |
|
| January 10, 2023 |
Exhibit 99.1 AMARIN PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 REVENUE AND CASH POSITION AND PRIORITIES FOR 2023 — Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements — — Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 — DUBLIN, Ireland and B |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation |
|
| January 10, 2023 |
EX-99.1 Exhibit 99.1 Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP. — Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board — — Ongoing Board Refreshment Program Has Led to Approximately 75% New Independent Directors Named to the Board Over the Last 12 Months — DUBLIN, Ireland and BRIDGEWATER, N.J., January 10, 2 |
|
| January 10, 2023 |
EX-99.2 Exhibit 99.2 st 41 Annual J.P. Morgan Healthcare Conference Karim Mikhail President & CEO January 23 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, g |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 (October 20, 2022) Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporatio |
|
| December 12, 2022 |
AMRN / Amarin Corporation plc (ADR) / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation |
|
| November 16, 2022 |
EX-99.1 November Investor Presentation November 16, 2022 Karim Mikhail President & CEO Exhibit 99.1 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic pr |
|
| November 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporatio |
|
| October 27, 2022 |
Exhibit 99.1 Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update - U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway - - Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – - Achieved Positive National Reimbursement in Finland & Obtained Positive Scientific Assessment for Reimbur |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation p |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| October 21, 2022 |
Exhibit 99.1 AMARIN APPOINTS ADAM BERGER AND GERALDINE MURPHY TO BOARD OF DIRECTORS Lars Ekman and Patrick O?Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New Independent Directors Appointed Over Last Twelve Months Amarin Continues Active Board Refreshment Program DUBLIN, Ireland |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 11, 2022 |
Exhibit 3 SARISSA CAPITAL HAS COMMENCED THE PROCESS TO CALL A SPECIAL MEETING OF AMARIN SHAREHOLDERS TO REMOVE AND REPLACE CERTAIN BOARD MEMBERS Sarissa believes Amarin risks destroying additional shareholder value unless Sarissa representatives are immediately added to the board Amarin board?s governance process lacks urgency and disregards shareholder vote at annual meeting Greenwich, CT, October 11, 2022 ? Sarissa Capital Management LP (?Sarissa?) today made the following statement regarding its ongoing discussions with Amarin Corporation plc (NASDAQ: AMRN) regarding board representation: Amarin?s board seems to be trying to outdo the misguided leadership of the Roman Emperor Nero who played his lyre while Rome was engulfed in flames. |
|
| October 11, 2022 |
AMRN / Amarin Corporation plc (ADR) / Sarissa Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| August 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation) |
|
| August 19, 2022 |
Amarin Provides Update on VAZKEPA® (icosapent ethyl) Pricing Negotiations in Germany Exhibit 99.1 Amarin Provides Update on VAZKEPA? (icosapent ethyl) Pricing Negotiations in Germany Frankfurt am Main, August 19, 2022 ? Amarin Deutschland GmbH today announced that after the conclusion of the fourth and final round of negotiations with the National Association of Statutory Health Insurance Funds (Spitzenverband der gesetzlichen Krankenversicherungen ? GKV-SV), a viable agreement on |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission on August 5, 2022 As filed with the Securities and Exchange Commission on August 5, 2022 Registration No. |
|
| August 5, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value 50 pence each (1) 457(c) and 457(h) 14,416,888(2) $1. |
|
| August 3, 2022 |
Offer Letter with Thomas Reilly, dated May 26, 2022* Exhibit 10.4 May 26, 2022 Mr. Thomas Reilly *** Dear Tom: On behalf of Amarin Corporation plc (the ?Company?), I am pleased to confirm our offer to employ you as Senior Vice President, Chief Financial Officer. The initial terms and conditions of your employment, should you accept this offer, are set forth below in this letter agreement (the ?Agreement?), 1. Position: Senior Vice President, Chief F |
|
| August 3, 2022 |
Form of Deferred Restricted Stock Unit Award Agreement* Exhibit 10.2 AMARIN CORPORATION plc 2020 STOCK INCENTIVE PLAN DEFERRED RESTRICTED STOCK UNIT AWARD AGREEMENT This AWARD AGREEMENT (the ?Agreement?) is entered into and made effective as of [ ], 20[ ] by and between Amarin Corporation plc (the ?Company?) and [ ] (the ?Participant?). The Company hereby grants to the Participant an award (the ?Award?) of deferred restricted stock units (the ?DSUs?) a |
|
| August 3, 2022 |
Exhibit 99.1 Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update Company Received Final Positive Reimbursement Decision for VAZKEPA? by UK?s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Initiated Comprehensive Cost Reduction Plan in June to Address Market Dynamics in the U.S. with Expe |
|
| August 3, 2022 |
Form of Restricted Stock Unit Award Agreement* Exhibit 10.3 AMARIN CORPORATION PLC 2020 STOCK INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This AWARD AGREEMENT (the ?Agreement?) is entered into and made effective as of [ ], 20[ ], by and between Amarin Corporation plc (the ?Company?) and [ ] (?Participant?). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Amarin Corporation |
|
| August 3, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (E |
|
| August 3, 2022 |
Amarin Pharma, Inc. 440 Route 22, Suite 300 Bridgewater, NJ 08807 (908)719-1315 Exhibit 10.5 June 6, 2022 (Revised) Mr. Michael W. Kalb 24 Lucille Lane Dix Hills, NY 11746 Re: Transition and Separation Agreement Dear Mike: This follows up on our recent discussions regarding your employment at Amarin Corporation, plc. (the "Company"). Per those discussions, you and the Company have agreed that your |
|
| June 30, 2022 |
Amendment No. 1 to 2020 Stock Incentive Plan* Exhibit 10.2 AMARIN CORPORATION PLC AMENDMENT NO. 1 TO 2020 STOCK INCENTIVE PLAN The Amarin Corporation plc 2020 Stock Incentive Plan (the ?Plan?) is hereby amended by the Board of Directors and shareholders of Amarin Corporation plc as follows: Section 2(w) of the Plan is hereby amended to read as follows: ?ISO Limit? shall mean 30,000,000 Shares, subject to adjustment as provided in the Plan and |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Co |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 16, 2022 |
EXHIBIT 2 SARISSA CAPITAL INTENDS TO VOTE ?ABSTAIN? AT THE AMARIN ANNUAL MEETING Sarissa intends to ?Abstain? given ongoing engagement with Amarin to add shareholder representatives to the board Greenwich, CT, June 15, 2022 ? Sarissa Capital Management LP (?Sarissa?) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN) regarding how it intends to vote at the upcoming Amarin annual meeting and the reasons therefor: Sarissa is a sophisticated, institutional investor with a long history of shareholder value creation in healthcare companies, including in the cardiovascular space, such as The Medicines Company. |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| June 6, 2022 |
EX-99.2 3 d100724dex992.htm EX-99.2 Exhibit 99.2 Amarin Appoints Tom Reilly as New Chief Financial Officer — Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin — — Michael W. Kalb to Depart Amarin to Pursue Other Interests — DUBLIN, Ireland and BRIDGEWATER, N.J., June 6, 2022 – Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Tom Rei |
|
| June 6, 2022 |
Exhibit 99.1 AMARIN ANNOUNCES COMPREHENSIVE COST REDUCTION PLAN TO ADDRESS MARKET DYNAMICS IN U.S. BUSINESS ? Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion ? ? Reduces U.S. Commercial Organization by Ninety Percent of Pre-Pandemic / Pre-Generic Competition Levels ? ? Creates Core F |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Amarin Corporation plc (Name of Issuer) Ordinary Shares, par value 50 pence per share (Title of Class of Securities) 023111206 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683 |
|
| May 24, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 20, 2022 |
Exhibit 99.1 Board Changes Press Release AMARIN ANNOUNCES APPOINTMENT OF NEW DIRECTORS AND BOARD LEADERSHIP CHANGES Erin Enright and Alfonso ?Chito? Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company?s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Bo |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 000-21392 Not applicable (State or other jurisdiction of incorporation) (C |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc ( |
|
| May 4, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2022 Amarin Corporation plc (Exact name of registrant as specified in its charter) England and Wales 0-21392 Not applicable (State or other jurisdiction of incorporation) (Comm |
|
| May 4, 2022 |
Exhibit 99.1 Amarin Reports First Quarter 2022 Financial Results and Provides Business Update Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets ? Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval of VASC |
|
| May 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| March 1, 2022 |
Exhibit 99.1 Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA? European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approval of VASCEPA in Several A |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 Amarin Corporation plc (Exact n |
|
| March 1, 2022 |
Exhibit 10.38 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT BY AND BETWEEN AMARIN PHARMACEUTICALS IRELAND LIMITED AMARIN CORPORATION PLC AND BIOPHARMA SECURED D |
|
| March 1, 2022 |
EXHIBIT 21.1 Subsidiaries of the Registrant as of December 31, 2021 Name Jurisdiction Amarin Pharmaceuticals Ireland Limited Ireland Amarin Pharma, Inc. United States Ester Neurosciences Limited Israel Amarin Switzerland GmbH Switzerland Amarin Germany GmbH Germany Amarin France SAS France Amarin UK Limited United Kingdom Amarin Italy S.r.l Italy Amarin Switzerland GmbH Sucursal Espana Spain Amari |
|
| March 1, 2022 |
Exhibit 10.54 English Summary of German Language Commercial Lease Agreement between Zug Estates AG and Amarin Switzerland GmbH Section Provision Terms and Conditions/Explanation Preamble Landlord Zug Estates AG, Industriestrasse 12, 6300 Zug Preamble Tenant Amarin Switzerland GmbH Preamble Building ?berbauung Metalli, Gotthardstrasse 2, 6300 Zug 1.1 Premises 1st floor, 419.10 sqm 1.1 Purpose Offic |
|
| March 1, 2022 |
Exhibit 10.37 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT This SECOND AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT (the ?Amendment?) i |
|
| March 1, 2022 |
Exhibit 10.36 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT This AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT (the ?Amendment?) is made as of t |
